

PRESS RELEASE

First study published on our blood test developed to detect rare neurological disease

Paris, France. June 12, 2017. **Teams from the AP-HP Paris public hospitals network, in collaboration with researchers from the Brain & Spine Institute (ICM) (Inserm/CNRS/UPMC), and Metafora biosystems, a start-up with links to the CNRS, have recently developed a diagnostic blood test for a rare but treatable condition called De Vivo disease.**

It was tested on 30 patients with the disease, which causes neurological deficits such as epilepsy and movement disorders.

Compared with current diagnostic tests that use an invasive procedure (lumbar puncture) or complex DNA analysis, this new test^[1], the results of which have been published in *Annals of Neurology*, will be able to screen for the condition rapidly (within 48h) and with ease in both adults and children.

De Vivo disease or glucose transporter type 1 deficiency syndrome (GLUT1-DS) is most often characterized by developmental delay, epilepsy and/or movement disorders in children. *Formes frustres*^[2] have been described in children (abnormal movement episodes) but also in adults. On the basis of an estimated prevalence of 1/83,000 in the Danish population, the number of those affected in the French population^[3] is thought to be 800, a little over one hundred of whom will be diagnosed. Once diagnosed, metabolic therapies are available to alleviate the symptoms.

Dr Fanny Mochel from AP-HP Pitié-Salpêtrière University Hospital, along with teams from other hospitals of the AP-HP network (Bichat, Raymond-Poincaré and Robert-Debré) and the Brain & Spine Institute (Inserm/CNRS/UPMC), have developed a simple and rapid (within 48h) diagnostic blood test for De Vivo in collaboration with Metafora biosystems. Current diagnosis is restrictive because it involves an invasive procedure (lumbar puncture) and complex genetic analysis.

In this study, blood samples from 30 De Vivo patients, with profiles differing according to age and symptoms, were analyzed. Following comparison with samples from 346 healthy controls, the results show that the test is significantly conclusive in that it identified 78% of the De Vivo patients, including those for whom the genetic analysis was inconclusive.

Backed by these results, the researchers recommend the use of this new test in routine clinical practice in all neuropediatric and neurology departments. They suggest that its simplicity should enable more patients to be diagnosed in France.

Thanks to this innovative novel blood test, it will be possible to screen for the disease in all patients presenting with cognitive impairment, movement disorders, epilepsy or a combination of the three. The therapies at our disposal can considerably improve symptoms,

including, for example, the control of epileptic seizures. However, since these are more effective when started early, timely diagnosis of the condition is crucial.

[1] Protected by patent CNRS WO2004/096841.

[2] When patients do not present all the characteristic symptoms of a disease or when such symptoms are mild

[3] [1] Larsen J, et al. The role of SLC2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome. *Epilepsia*. 2015 Dec;56(12):e203-8.

A simple blood test expedites the diagnosis of GLUT1 deficiency syndrome

Domitille Gras (1), Christelle Cousin (2), Caroline Kappeler (3), Cheuk-Wing Fung (4), Stéphane Auvin (1,5), Nouha Essid (6), Brian Hy Chung (4), Lydie Da Costa (7,8), Elodie Hainque (3,9), Marie-Pierre Luton (3), Vincent Petit (2), Sandrine Vuillaumier-Barrot (10), Odile Boespflug-Tanguy (1), Emmanuel Roze (3,9), Fanny Mochel (3,11,12)

(1) APHP, Robert-Debré University Hospital, Department of Paediatric Neurology and Metabolic Diseases, Paris, France

(2) Metafora Biosystems, Evry, France

(3) Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France

(4) Queen Mary Hospital, Department of Pediatrics and Adolescent Medicine, Hong-Kong

(5) Inserm U 1141, Université Paris Diderot, Sorbonne Paris Cité, DHU Protect, Paris, France

(6) APHP, Raymond-Poincaré Hospital, Department of Neuropediatrics, Paris, France

(7) APHP, Robert-Debré University Hospital, Laboratory of Hematology, Paris, France

(8) Inserm U 1134; LABEX Gr-Ex ; Université Paris Diderot, Paris, France

(9) APHP, Pitié-Salpêtrière University Hospital, Department of Neurology, Paris, France

(10) AP-HP, Bichat-Claude Bernard Hospital, Biochemistry and Genetic Laboratory, Paris, France

(11) APHP, Pitié-Salpêtrière University Hospital, Department of Genetics, Paris, France

(12) University Pierre and Marie Curie, Neurometabolic Research Group, Paris, France

Annals of Neurology, 25 mai 2017

DOI : 10.1002/ana.24970

About AP-HP

AP-HP is a world-renowned university hospital system and major clinical research player in France and Europe. Its 39 hospitals receive 8 million patients every year for consultations, emergency treatment, scheduled admissions and in-home healthcare. It provides a round-the-clock public health service for all, which for AP-HP is a matter of both duty and pride. With its 95,000 members of staff – doctors, researchers, allied medical staff, administrative staff and other employees, AP-HP is the leading employer in Ile-de-France.

www.aphp.fr

About CNRS

The French National Center for Scientific Research is a public research institution under the authority of the French Ministry of National Education, Higher Education and Research. It produces knowledge for the benefit of society. With nearly 32,000 staff members, an initial 2015 budget of 3.3 billion euros including 769 million euros of its own resources, and facilities throughout France, the CNRS is present in all fields of knowledge through its 1,100 research and service units. With a portfolio of 5,629 patent families, 1,281 active licenses, 21 framework agreements with listed companies, 376 industrial joint-ownership agreements, 851 institutional joint-ownership agreements, more than 1,200 established start-ups, more than 120 public/private research structures, 152 laboratories involved with 27 Carnot Institutes and 433 in the competitiveness clusters, a yearly average of 43,000 publications, 21 Nobel Laureates and 12 Fields Medal winners, the CNRS has a long tradition of excellence, innovation and transfer of knowledge to the economy.

www.cnrs.fr

About Inserm

Founded in 1964, the French National Institute of Health and Medical research (Inserm) is a public science and technology institute, jointly supervised by the French Ministry of National Education, Higher Education and Research and the Ministry of Social Affairs and Health. Inserm is the only French public research institute dedicated to biomedical research and human health, with nearly 15,000 researchers, engineers, technicians, university hospital employees and post-doctoral students, and some 300 laboratories. The mission of its researchers is to study all diseases, from the most common to the most rare. Inserm is a founding member of Aviesan*, the French National Alliance for Life Sciences and Health created in 2009.

*Other founding members of Aviesan: CEA, CNRS, CHRU, CPU, INRA, INRIA, Inserm, Institut Pasteur, IRD
Access the press room ;
Follow Inserm on Twitter: @Inserm

About METAFORA biosystems

METAFORA biosystems is a young, innovative company based at Genopole®, Evry, France. The company is developing an innovative technology, the only one able to assess cells' nutrition needs simply and quickly, thereby assessing and detecting abnormalities in their energy needs. Proprietary reagents, under patent license from CNRS, and cutting-edge algorithms are at the heart of the technology platform, and enable the readout of "metabolic reprogramming", induced during numerous pathological processes. METAFORA technology, which has been widely published in fundamental research articles in leading journals, is now being deployed in routine clinical practice in order to bring this innovation to patients.

www.metafora-biosystems.com

Press contact

AP-HP Press Office:

Juliette Hardy & Marine Leroy - +33 (0)1 40 27 37 22 - service.presse@aphp.fr

